NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in RRMM Multiple Myeloma
NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell maturation antigen (BCMA), as measured by the incidence of dose-limiting toxicities (DLTs). Participants will be given a 3 day course of conditioning chemotherapy followed by a single infusion of KITE-585.
Sponsor
ClinicalTrials.gov Identifier: NCT04892446
Official Title: A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma
First Posted : October 24, 2017
Click here for details on ClinicalTrials.gov
Autologous Anti-BCMA CAR-transduced T-cells KITE-585 (Code C155883)
Autologous Anti-BCMA CAR-transduced T-cells KITE-585
Autologous Genetically Modified Anti-BCMA CAR-T Cells KITE-585
Autologous Genetically-modified Anti-BCMA CAR-transduced T-cells KITE-585
Autologous T-cells KITE-585
KITE 585
KITE-585
KITE585
Genetic: KITE-585
Drug: Cyclophosphamide
Drug: Fludarabine
Am J Cancer Res; 2021 Jun 15
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma
Location
United States, California
United States, Florida
United States, Georgia
United States, Illinois
United States, Massachusetts
United States, Minnesota
United States, New York
United States, Tennessee
United States, Texas